A Psychedelic Development and Wellness Company

Trip Pharma is currently pursuing the buildout of a purpose-built facility that will provide a supply of high-quality products for use in research and prescription for clinical patients. Trip Pharma intends to conduct research in psilocybin producing mushrooms, is in the process of submitting an application for a Controlled Drugs and Substances Dealers License in Canada and is working to source a library of Psilocybin Cubensis genetics.

Trip Pharma also plans to develop a psychiatric research clinic where patients are able to access care, as well as complementary treatments, in a welcoming and stigma-free environment. If and when Trip Pharma receives its dealers license, the clinic intends to conduct research into the use of psilocybin for the treatment of depression, anxiety, post-traumatic stress, chronic pain and fatigue, sleep disorders, sexual dysfunction, and attention deficit symptomatology, and then meet with patients to gauge their interest in the use of psilocybin as a potential therapy.

A leader in Psychedelics for Medical Treatment

With the current breakthroughs in psychedelic research & novel approaches to using psychedelics for medical treatment, Trip Pharma intends to be a leader in researching the use of psilocybin as an alternative medical treatment, MDMA and other peripheral substances through its application for a Controlled Drugs and Substances Dealers License.

Our purpose-built facility will ensure a steady supply of high quality product for use in research and prescription for clinical patients. Our company’s near-term goal is to house a physical clinic where patients are able to access alternatives to current psychiatric care, as well as complementary treatments, in a welcoming and stigma-free environment.

A problem that affects us all.

Psychedelic therapy is poised to be the leading edge in Mental Health and Medical treatments.

Much existing research from around the world indicates that psychedelics have considerable efficacy in many Mental Health applications, Chronic Pain and Fatigue, and Metabolic issues such as weight regulation.

20%

20% of people in Canada will personally experience a mental health problem or illness.

THIRD
HIGHEST

Canada’s youth suicide rate the third highest in the industrialized world.

8%

Approximately 8% of adults will experience major depression at some time in their lives.

50%

By age 40, about 50% of the population will have or have had a mental illness.

24/16

Suicide accounts for 24% of all deaths among 15-24 year olds and 16% among 25-44 year olds.

50%

Almost 50% of those who feel they have suffered from depression or anxiety have never gone to see a doctor about this problem.

3.2M

The total number of 12-19 year olds in Canada at risk for developing depression is a staggering 3.2 million.

SECOND
HIGHEST

Mental disorders in youth are ranked as the second highest hospital care expenditure in Canada.

Our Clinic

Led by Dr. Krista Leicht, our clinic is a multidisciplinary clinic, on the cutting edge of innovative treatments. The clinic will offer patients alternatives to conventional psychiatric and medical therapy for a wide variety of issues and conditions.

Aimed to offer both conventional and alternative therapies to help treat depression, mood disorders, anxiety, metabolic dysregulation and chronic pain among many others.

The Trip Pharma Method

Fruiting Method

Our fruiting method produces extremely visually appealing as well as consistently potent results.

Harvest Method

Our harvest method ensures the fruit is not bruised or damaged while maintaining visual appeal.

Dehydration Method

Our dehydration method is extremely controlled, ensuring minimal loss of potency due to oxidation of psilocin and psilocybin.

Learn More

Looking for more information?

View Our Presentation

Have some questions? Get in touch with us.

Contact Us